Abstract: The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO?), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
Abstract: The present invention relates to an injectable pharmaceutical composition with gelling properties containing: -an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein the organogelling substance is chosen among L-tyrosine derivatives responding to the following formula (I) wherein: R1 is an alkyl group containing 1 to 3 carbon atoms, linear or branched; and R2 is a hydrophobic group chosen among aliphatic saturated or unsaturated fatty chains or aryl or arylalkyl groups. Its use as a vector for the release of active principles, as well as its process of preparation.
Abstract: The present invention relates to the use of a sustained release matrix containing at least one opioid for producing a solid oral formulation in table form suitable for reducing blood concentration fluctuations of said opioid.
Abstract: The present invention relates to a coated particle of active substance comprising a core, said core comprising the active substance and an acidic compound, said core being coated with a taste masking coating based on a polymer which is soluble at pH of 5 or less, and which is permeable at pH above 5.
Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables to enhance the bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.
Abstract: An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.
Abstract: The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.
Type:
Grant
Filed:
June 25, 2010
Date of Patent:
October 22, 2013
Assignee:
Ethypharm
Inventors:
Bruno Criere, Pascal Suplie, Philippe Chenevier
Abstract: Pharmaceutical compositions comprising micronized fenofibrate, a surfactant and a binding cellulose derivative as a solubilization adjuvant, wherein said compositions contain an amount of fenofibrate greater than or equal to 60% by weight and methods of producing fenofibrate compositions.
Type:
Grant
Filed:
January 13, 2010
Date of Patent:
September 10, 2013
Assignee:
Ethypharm
Inventors:
Bruno Criere, Pascal Suplie, Philippe Chenevier, Pascal Oury, Keith S. Rotenberg, George Bobotas
Abstract: Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa.
Type:
Grant
Filed:
March 1, 2007
Date of Patent:
August 6, 2013
Assignee:
Ethypharm SA
Inventors:
Vincent Cailly-Dufestel, Catherine Herry, Johnatan Bacon, Pascal Oury
Abstract: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
Abstract: The invention relates to the use of an oral dosage form based on microgranules and/or microtablets to reduce the abusive use of at least one active principle contained therein. The aim of the invention is to prevent the diversion of an oral dosage form based on microgranules and/or microtablets containing at least one active principle capable of causing a dependency, a gelling agent, and a gelling activator. The gelling agent and the activator are only brought into contact with each other in the event of diversion by crushing. Said judiciously selected pair of excipients confers a viscosity to the formulation, such that said formulation cannot be administered by injection or does not release the active principle rapidly by forming a gel when it comes into contact with the mucous membrane if nasally administered.
Abstract: The invention relates to a pharmaceutical form for combating chemical submission, comprising an active ingredient and at least one compound which enables immediate modification of the organoleptic characteristics of a beverage into which the pharmaceutical form is introduced, said compound being selected from the group comprising an opacifier, a fluorescent agent, floating particles, particles that are perceptible in the mouth, effervescent microgranules, and mixtures thereof; it also relates to the use of these compounds for combating chemical submission and to a method for combating chemical submission using said pharmaceutical forms.
Abstract: A pharmaceutical formulation of a gastric proton pump inhibitor, with the exception of omeprazole, is disclosed. The formulation is in the form of microgranules insoluble in gastric fluid having improved stability over time. The formulation comprises several hydrophobic substances chosen in order to increase the stability of the active principle while obtaining the desired dissolution profile.
Type:
Grant
Filed:
May 19, 2000
Date of Patent:
April 2, 2013
Assignee:
Ethypharm
Inventors:
Bruno Criere, Pascal Suplie, Pascal Oury
Abstract: A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load in relation to dry weight of hydrophobic coating polymer. The pharmaceutical form has improved resistance to rapid release of active ingredient, particularly in the presence of alcohol.
Abstract: The invention concerns a rapidly disintegrating tablet similar to those designed to disintegrate in the mouth on contact with saliva in less than 30 seconds, forming an easy-to-swallow suspension, and based on an active substance in the form of coated microcrystals or microgranules and a mixture of excipients including at least a disintegrating agent, a soluble agent and a lubricating agent. The invention is characterized in that the lubricating agent is in powder form and is distributed at least for the greater part on the tablet surface and its friability, measured as specified in the French Pharmacopoeia (10th Edition, V.5.1—Friability of Tablets, January 1993), is less than 1%, and preferably less than 0.
Type:
Grant
Filed:
February 29, 2000
Date of Patent:
February 19, 2013
Assignee:
Ethypharm
Inventors:
Laurent Di Costanzo, Edouard André Gendrot, Mathieu Ernest Jean-Baptiste Di Costanzo, Charles André Chauveau
Abstract: The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterised in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste.
Type:
Application
Filed:
August 16, 2012
Publication date:
February 14, 2013
Applicant:
ETHYPHARM
Inventors:
Guy Couaraze, Bernard Leclerc, Pierre Tchoreloff, Patrick Sanial
Abstract: The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterized in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste.
Type:
Grant
Filed:
July 25, 2000
Date of Patent:
December 25, 2012
Assignee:
ETHYPHARM
Inventors:
Guy Couaraze, Bernard Leclerc, Pierre Tchoreloff, Patrick Sanial